Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A PHASE-II CLINICAL-TRIAL OF INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER-CELLS IN ADVANCED COLORECTAL-CARCINOMA
Autore:
HAWKINS MJ; ATKINS MB; DUTCHER JP; FISHER RI; WEISS GR; MARGOLIN KA; RAYNER AA; SZNOL M; PARKINSON DR; PAIETTA E; GAYNOR ER; BOLDT DH; DOROSHOW JH; ARONSON FR;
Indirizzi:
NCI,DIV CANC TREATMENT,CANC THERAPY EVALUAT PROGRAM,INVEST DRUG BRANCH BETHESDA MD 20892 NCI,DIV CANC TREATMENT,CANC THERAPY EVALUAT PROGRAM,INVEST DRUG BRANCH BETHESDA MD 20892 TUFTS UNIV NEW ENGLAND MED CTR BOSTON MA 02111 ALBERT EINSTEIN CANC CTR NEW YORK NY 00000 LOYOLA UNIV,MED CTR MAYWOOD IL 60153 UNIV TEXAS SAN ANTONIO TX 78285 CITY HOPE CANC RES CTR DUARTE CA 00000 UNIV CALIF SAN FRANCISCO SAN FRANCISCO CA 00000
Titolo Testata:
Journal of immunotherapy with emphasis on tumor immunology
fascicolo: 1, volume: 15, anno: 1994,
pagine: 74 - 78
SICI:
1067-5582(1994)15:1<74:APCOIA>2.0.ZU;2-6
Fonte:
ISI
Lingua:
ENG
Soggetto:
RECOMBINANT INTERLEUKIN-2; CANCER; THERAPY; IMMUNOTHERAPY; TOXICITY;
Keywords:
INTERLEUKIN-2; LYMPHOKINE-ACTIVATED KILLER CELLS; COLORECTAL CARCINOMA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
12
Recensione:
Indirizzi per estratti:
Citazione:
M.J. Hawkins et al., "A PHASE-II CLINICAL-TRIAL OF INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER-CELLS IN ADVANCED COLORECTAL-CARCINOMA", Journal of immunotherapy with emphasis on tumor immunology, 15(1), 1994, pp. 74-78

Abstract

Patients (n = 22) with metastatic or unresectable colorectal carcinoma were treated with interleukin (IL)-2 and lymphokine-activated killer(LAK) cells in a phase II study conducted by the IL-2/LAK Working Group (ILWG). Eligibility criteria for the study included bidimensionallymeasurable disease, performance status 0 or 1, and normal function ofall vital organs. The median age of patients was 49 (range, 28-61) years. Eight (36%) patients had never received prior treatment other than their initial surgery; eight (36%) had received prior radiotherapy, and 12 (55%) chemotherapy. No patients had received prior immunotherapy. Treatment consisted of IL-2, 600,000 IU/kg administered by 15-min intravenous infusion every 8 h on days 1-5 and 12-16. Patients underwent 4-h leukapheresis on days 8-12, and cells were placed in in vitro culture with IL-2 for 3-4 days and the activated LAK cells were infused over 1 h on days 12, 13, and 15. All doses of IL-2 and LAK cells were administered to patients in intensive care unit (ICU) settings. The mean +/- SD number of IL-2 doses administered during days 1-5 was 13.4 +/- 1.2, the mean number of LAK cells reinfused was 6.8 +/- 2.2 x 10(10), and the mean number of IL-2 doses administered during the last phase was 9.8 +/- 2.5. Nineteen patients completed the IL-2 priming phase and received at least one LAK cell infusion. One patient achieved a complete response and was progression free for 8 months from the beginning of treatment, for an overall objective response rate of 5% (95% confidence interval: 0-13%). Hypotension, weight gain, anemia, and elevations of serum creatinine and liver enzymes were common, but there wereno treatment-related deaths. Treatment delivered and toxicity were comparable to those reported in studies conducted concurrently for othermalignancies. We conclude that high-dose IL-2 has minimal activity inmetastatic colorectal cancer; however, the low level of activity should not preclude future studies combining IL-2 with other immunotherapeutic approaches.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 10:12:30